The objectives of the Center for Studies of Host Response to Cancer Therapy are to (1) form a self- sustaining multidisciplinary research center within the University of Arkansas for Medical Sciences (UAMS) that examines mechanisms of and prevention strategies for cancer-therapy-induced toxicity and (2) help junior investigators with a common research focus establish themselves as independent scientists. Achieving these goals will create a vibrant, synergistic research environment to comprehensively address the mechanisms of side effects of cancer therapy and to develop effective strategies to prevent such side effects. To our knowledge, few centers exist that focus on cancer survivors, and none take the paradigm-shifting approach of proactively addressing treatment-related toxicities. Specifically, this Center will provide an environment for young investigators to succeed as independent scientists (Aim 1); strengthen the overall research infrastructure at UAMS and the Cancer Institute (Aim 2); and ensure that the Center for Studies of Host Response to Cancer Therapy becomes self-sustaining (Aim 3). The four initial Project Leaders are promising new/early-stage investigators with their own active research programs and established collaborations with fellow Project Leaders and/or mentors. All are in the tenure track with their own research laboratories, and all have been provided generous institutional startup packages by their departments. Opportunities will be provided by implementing individualized mentoring and faculty development plans and by offering guidance and support from an administrative and two scientific cores. A high likelihood of success is ensured by strong institutional support combined with active interest from funding agencies in improving quality of life among cancer survivors. To replace Project Leaders who achieve independence and graduate from COBRE support, a pipeline of new Project Leaders is ensured through institutional support for recruitment of junior faculty, combined with a structured pilot project program. Building strong Center cores and collaborations with existing institutional cores will also contribute to establishing the Center for Studies of Host Response to Cancer Therapy as a self-sustaining center on campus. The Center's progress will be guided by External and Internal Advisory Committees and a Core Oversight Committee. The Internal Advisory Committee, comprised of individuals in key positions, with broad representation from across the institution and with a vested interest in the Center's achievements, will ensure the initial success of the Center as well as its long-term viability as an independent unit on campus.

Public Health Relevance

Many cancer survivors cured of their original malignancy suffer from treatment-related problems, ranging from mild psychosocial disabilities to life-threatening physical sequelae. Comparatively little effort has been directed toward determining the mechanisms that are responsible for side effects that persist after cancer therapy and at developing effective interventions to prevent them. This COBRE Center addresses these unmet needs and ensures that advances in oncology go hand in hand with efforts to optimize the quality of life of cancer survivors, thereby maximizing the number of uncomplicated cancer cures.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
5P20GM109005-03
Application #
9249611
Study Section
Special Emphasis Panel (ZGM1-TWD-A (1C))
Program Officer
Liu, Yanping
Project Start
2015-06-24
Project End
2020-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
3
Fiscal Year
2017
Total Cost
$1,904,629
Indirect Cost
$626,354
Name
University of Arkansas for Medical Sciences
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Luo, Yi; Shao, Lijian; Chang, Jianhui et al. (2018) M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion. Blood Adv 2:859-870
Alexander, Tyler C; Simecka, Christy M; Kiffer, Frederico et al. (2018) Changes in cognition and dendritic complexity following intrathecal methotrexate and cytarabine treatment in a juvenile murine model. Behav Brain Res 346:21-28
Liu, Xingui; Wang, Yingying; Zhang, Xuan et al. (2018) Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation. Bioorg Med Chem 26:3925-3938
Nukala, Ujwani; Thakkar, Shraddha; Krager, Kimberly J et al. (2018) Antioxidant Tocols as Radiation Countermeasures (Challenges to be Addressed to Use Tocols as Radiation Countermeasures in Humans). Antioxidants (Basel) 7:
Yadlapalli, Jai Shankar K; Dogra, Navdeep; Walbaum, Anqi W et al. (2018) Pinprick hypo- and hyperalgesia in diabetic rats: Can diet content affect experimental outcome? Neurosci Lett 673:24-27
Nekouei, Mina; Ghezellou, Parviz; Aliahmadi, Atousa et al. (2018) Changes in biophysical characteristics of PFN1 due to mutation causing amyotrophic lateral sclerosis. Metab Brain Dis 33:1975-1984
Cheema, Amrita K; Byrum, Stephanie D; Sharma, Neel Kamal et al. (2018) Proteomic Changes in Mouse Spleen after Radiation-Induced Injury and its Modulation by Gamma-Tocotrienol. Radiat Res 190:449-463
Skinner, Charles M; Miousse, Isabelle R; Ewing, Laura E et al. (2018) Impact of obesity on the toxicity of a multi-ingredient dietary supplement, OxyELITE Pro™ (New Formula), using the novel NZO/HILtJ obese mouse model: Physiological and mechanistic assessments. Food Chem Toxicol 122:21-32
Alam, Sinthia; Carter, Gwendolyn S; Krager, Kimberly J et al. (2018) PCB11 Metabolite, 3,3'-Dichlorobiphenyl-4-ol, Exposure Alters the Expression of Genes Governing Fatty Acid Metabolism in the Absence of Functional Sirtuin 3: Examining the Contribution of MnSOD. Antioxidants (Basel) 7:
Barham, Caroline; Fil, Daniel; Byrum, Stephanie D et al. (2018) RNA-Seq Analysis of Spinal Cord Tissues from hPFN1G118V Transgenic Mouse Model of ALS at Pre-symptomatic and End-Stages of Disease. Sci Rep 8:13737

Showing the most recent 10 out of 81 publications